HighVista Strategies LLC Has $3.50 Million Stake in Celldex Therapeutics, Inc. $CLDX

HighVista Strategies LLC increased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 26.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 135,258 shares of the biopharmaceutical company’s stock after acquiring an additional 28,705 shares during the quarter. HighVista Strategies LLC’s holdings in Celldex Therapeutics were worth $3,499,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CLDX. Eventide Asset Management LLC lifted its holdings in Celldex Therapeutics by 37.1% during the 3rd quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock valued at $48,096,000 after purchasing an additional 502,909 shares during the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of Celldex Therapeutics in the third quarter valued at $372,000. Bank of America Corp DE increased its holdings in shares of Celldex Therapeutics by 22.7% in the third quarter. Bank of America Corp DE now owns 338,811 shares of the biopharmaceutical company’s stock valued at $8,765,000 after purchasing an additional 62,627 shares during the last quarter. Braidwell LP bought a new position in shares of Celldex Therapeutics in the third quarter valued at about $15,307,000. Finally, Creative Planning raised its position in shares of Celldex Therapeutics by 11.3% in the third quarter. Creative Planning now owns 33,270 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 3,368 shares during the period.

Celldex Therapeutics Stock Down 1.2%

CLDX stock opened at $29.51 on Monday. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -7.59 and a beta of 1.17. The company’s fifty day simple moving average is $26.34 and its 200 day simple moving average is $26.01. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $31.99.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%.The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. Research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on CLDX shares. Barclays lifted their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus restated a “buy” rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Finally, The Goldman Sachs Group increased their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.50.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.